Consensus analyst expectations for Solid Biosciences LLC point to second-quarter revenue of $0.00 and an EPS loss of $0.43, while the stock currently trades near $8.55 against an average price target of $16.00.
The primary focus for investors this quarter is the clinical execution of SGT-003, the company's next-generation gene therapy for Duchenne Muscular Dystrophy.
Market participants are specifically looking for safety updates from the Phase 1/2 INSPIRE trial and progress on the newly initiated Phase 3 IMPACT study. With a recently bolstered cash position extending the company's runway into mid-2028, analysts are evaluating the sustainability of increased R&D spending as the pipeline transitions toward late-stage regulatory milestones.